CLSA PREMIUM (06877) announced that the Board expects the Group to make an unaudited net profit of approximately HK $5.2 million and an unaudited consolidated net loss of approximately HK $17.5 million for the same period in 2022.
The expected net profit is mainly a combination of the growth of the healthcare products business in the first half of 2023 and the continued efforts of the Group to streamline operations and improve business efficiency, resulting in a reduction in expenditure in the first half of 2023 compared with the first half of 2022, including staff costs of about HK $7.6 million and IT maintenance and support expenses of about HK $1.2 million.